Sorafenib-induced erythema multiforme

J Am Acad Dermatol. 2007 Mar;56(3):527-8. doi: 10.1016/j.jaad.2006.10.981. Epub 2007 Jan 22.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Administration, Oral
  • Benzenesulfonates / administration & dosage
  • Benzenesulfonates / adverse effects*
  • Benzenesulfonates / therapeutic use
  • Erythema Multiforme / chemically induced*
  • Female
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary
  • Melanoma, Amelanotic / drug therapy
  • Melanoma, Amelanotic / secondary
  • Middle Aged
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyridines / administration & dosage
  • Pyridines / adverse effects*
  • Pyridines / therapeutic use
  • Sorafenib

Substances

  • Benzenesulfonates
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Pyridines
  • Niacinamide
  • Sorafenib